Ocugen Announces Completion of 50% of Enrollment of its Phase 3 Clinical Trial for ocular GVHD
MALVERN, PA — Ocugen, Inc., (NASDAQ: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases, announced that it …
Read More